Skip to main content

SAIL share price gains on 50% jump in July sales

The company said its total sales grew by about 50 percent on year to 15.83 lakh tonnes during July 2020. The company had registered sale of 10.59 LT steel during the same month last year, it said.

 

Steel Authority of India Ltd (SAIL) share price jumped over 4 percent in the morning trade on August 5 after the steel maker reported robust sales growth in July 2020.

The company said its total sales grew by about 50 percent year-on-year to 15.83 lakh tonnes during July 2020. The company had registered sale of 10.59 LT steel during the same month last year, Steel Authority of India Ltd (SAIL) said in a statement.

 

The stock price has gained over 24 percent in the last three months and was trading at Rs 35.95, up Rs 1.40, or 4.05 percent at 09:40 hours. It touched an intraday high of Rs 36.10 and an intraday low of Rs 35.10.

The stock was one of the most active stocks on NSE in terms of volumes with 99,41,868 shares being traded.

The company sold 12.73 LT steel in the domestic market and exported 3.10 LT steel in July, a growth of 29 percent and 349 percent, respectively, over the year-ago month.

"SAIL is working hard to improve the overall performance. The efforts being put in have started showing in these record sales numbers, reduced inventory, improved collections and reduced borrowings," the company's chairman Anil Kumar Chaudhary said. "SAIL is focused on reducing on its borrowings further towards meeting the expectation of all our stakeholders," he added.


According to Moneycontrol SWOT Analysis powered by Trendlyne, the company has strong cash-generating ability from core business - improving cash flow from operation for the last two years. It has zero promoter pledge as well.


Source - Moneycontrol.com

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...